Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European Commission Initiated DalcA Phase 2b Trial for the Treatment of …